AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
AIM ImmunoTech (NYSE American: AIM) has announced it will postpone its planned offering under Registration Statement Form S-1. The company will not proceed with the offering until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
AIM ImmunoTech (NYSE American: AIM) ha annunciato che posticiperà l'offerta pianificata ai sensi del Modulo di Registrazione S-1. La società non procederà con l'offerta fino a dopo aver presentato il suo Rapporto Annuale nel Modulo 10-K per l'esercizio fiscale conclusosi il 31 dicembre 2024.
AIM ImmunoTech (NYSE American: AIM) ha anunciado que pospondrá su oferta planificada bajo la Declaración de Registro Formulario S-1. La compañía no procederá con la oferta hasta después de presentar su Informe Anual en el Formulario 10-K para el año fiscal que finaliza el 31 de diciembre de 2024.
AIM ImmunoTech (NYSE American: AIM)은 등록신고서 양식 S-1에 따라 예정된 제안을 연기한다고 발표했습니다. 이 회사는 2024년 12월 31일로 종료된 회계연도에 대한 연례 보고서를 제출한 후에야 제안을 진행할 것입니다.
AIM ImmunoTech (NYSE American: AIM) a annoncé qu'elle reporte son offre prévue sous le formulaire d'enregistrement S-1. La société ne procédera pas à l'offre avant d'avoir soumis son Rapport Annuel sur le formulaire 10-K pour l'exercice fiscal clos le 31 décembre 2024.
AIM ImmunoTech (NYSE American: AIM) hat angekündigt, das geplante Angebot unter dem Registrierungsformular S-1 zu verschieben. Das Unternehmen wird das Angebot nicht durchführen, bis der Jahresbericht auf Formular 10-K für das zum 31. Dezember 2024 endende Geschäftsjahr eingereicht wurde.
- None.
- Delayed S-1 offering indicates potential delay in raising capital
- Postponement of offering may impact company's near-term funding plans
Insights
The postponement of AIM ImmunoTech's planned offering represents a significant shift in their capital raising strategy. This decision to delay until after the 10-K filing suggests several critical implications for investors. First, it indicates a strategic approach to ensure full transparency, as potential investors will have access to the most current annual financial data before making investment decisions.
However, this delay could potentially impact the company's immediate capital needs. With a market cap of approximately
The timing of this announcement, combined with the decision to wait for the annual report, might suggest management's confidence in their upcoming financial results or potentially significant developments that would be detailed in the 10-K. This comprehensive disclosure approach, while causing a short-term delay, could actually strengthen the offering's prospects by providing potential investors with a complete picture of the company's financial position and operational progress.
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. No assurance can be given as to whether the Company will proceed with an offering. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
FAQ
Why did AIM ImmunoTech delay its Form S-1 offering in February 2025?
When will AIM ImmunoTech proceed with its planned offering?
What is the impact of AIM's delayed S-1 offering on its financing plans?
What regulatory filings must AIM complete before proceeding with its offering?
